Cost-Effectiveness Evaluation of Add-on Empagliflozin in Patients With Heart Failure and a Reduced Ejection Fraction From the Healthcare System's Perspective in the Asia-Pacific Region
Published in
Frontiers in Cardiovascular Medicine, October 2021
Pharmacology, Toxicology and Pharmaceutical Science
2
9%
Unknown
18
78%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 June 2022.
All research outputs
#17,664,478
of 22,675,759 outputs
Outputs from Frontiers in Cardiovascular Medicine
#2,710
of 6,554 outputs
Outputs of similar age
#292,902
of 435,487 outputs
Outputs of similar age from Frontiers in Cardiovascular Medicine
#278
of 760 outputs
Altmetric has tracked 22,675,759 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 6,554 research outputs from this source. They receive a mean Attention Score of 3.7. This one has gotten more attention than average, scoring higher than 52% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 435,487 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 760 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.
